1)大腸癌研究会:大腸癌診療ガイドライン 医師用2016年度版.金原出版,2016,pp 22-24
2)Adam R, Wicherts DA, de Haas RJ, et al:Patients with initially unresectable colorectal liver metastases:is there a possibility of cure? J Clin Oncol 27:1829-1835, 2009
3)Huguet F, André T, Hammel P, et al:Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase Ⅱ and Ⅲ studies. J Clin Oncol 25:326-331, 2007
4)Van Cutsem E, Köhne CH, Láng I, et al:Cetuximab plus irinotecan, fluorouracil, and leucovorin as first line treatment for metastatic colorectal cancer:updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011-2019, 2011
5)Bokemeyer C, Bondarenko I, Hartmann JT, et al:Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer:the OPUS study. Ann Oncol 22:1535-1546, 2011
6)Douillard JY, Siena S, Cassidy J, et al:Randomized, phase Ⅲ trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin(FOLFOX4)versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer:the PRIME study. J Clin Oncol 28:4697-4705, 2010
7)Folprecht G, Gruenberger T, Bechstein WO, et al:Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab:the CELIM randomised phase 2 trial. Lancet Oncol 11:38-47, 2010
8)Imura S, Shimada M, Utsunomiya T, et al:A modified liver-hanging maneuver focusing on the ligamentum venosum for left hepatic lobectomy. Surg Today 42:720-723, 2012